Enveda Raises $311M to Advance AI-Discovered Nature Drugs
Biotech startup doubles valuation as it pushes nature-derived candidates into clinical trials.
Enveda Biosciences secured $311 million in Series E funding to accelerate AI-discovered drugs from plants and microbes into human trials, doubling its $2 billion valuation.